COL17A1

Across TCGA pan-cancer cohorts, COL17A1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COL17A1 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher COL17A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL17A1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where COL17A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.397	0.872	.002	14	view →
HNSC	DFS	Tertile	III,IV	1.000	0.904	.019	12	view →
LUAD	DFS	Tertile	All	0.853	0.993	.018	9	view →
PDAC	DFS	Tertile	II,III,IV	0.320	0.530	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COL17A1–LSCC (DFS)

Open the LSCC breakdown →